EXPRESS MAIL NO: EL897872495US

PATENT

=#9a T.B.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants

W. Michael Kavanaugh et al.

Application No.

09/640,041

Filed

August 15, 2000

For

EGFH2 GENES AND GENE PRODUCTS

Examiner

M. Jamroz

Art Unit

1644

Docket No.

PP-01615.002/200130.503

Date

November 29, 2001

Commissioner for Patents U.S. Patent and Trademark Office P.O. Box 2327 Arlington, VA 22202

PRELIMINARY AMENDMENT REGARDING SEQUENCE DISCLOSURES

Commissioner for Patents:

In response to the Restriction Requirement dated October 30, 2001 please amend the above-identified application as follows:

In the Specification:

Please insert the enclosed "Sequence Listing" immediately after the section of the specification entitled "Abstract of the Disclosure" on page 47.

Please replace the paragraph beginning at page 12, line 11, with the following rewritten paragraph:

Fusion proteins comprising EGFH2 or a biologically active or antigenic fragment thereof can be produced using methods known in the art. Such fusion proteins can be used therapeutically or can be produced in order to simplify the isolation and purification procedures.

